Correlation Between ProPhase Labs and XTL Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both ProPhase Labs and XTL Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ProPhase Labs and XTL Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ProPhase Labs and XTL Biopharmaceuticals Ltd, you can compare the effects of market volatilities on ProPhase Labs and XTL Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ProPhase Labs with a short position of XTL Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of ProPhase Labs and XTL Biopharmaceutica.

Diversification Opportunities for ProPhase Labs and XTL Biopharmaceutica

0.57

Correlation Coefficient

ProPhase Labs  XTL Biopharmaceutica

Very weak diversification

The 3 months correlation between ProPhase and XTL is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding ProPhase Labs and XTL Biopharmaceuticals Ltd in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on XTL Biopharmaceuticals and ProPhase Labs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ProPhase Labs are associated (or correlated) with XTL Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of XTL Biopharmaceuticals has no effect on the direction of ProPhase Labs i.e., ProPhase Labs and XTL Biopharmaceutica go up and down completely randomly.

Pair Corralation between ProPhase Labs and XTL Biopharmaceutica

Given the investment horizon of 90 days ProPhase Labs is expected to under-perform the XTL Biopharmaceutica. But the stock apears to be less risky and, when comparing its historical volatility, ProPhase Labs is 1.02 times less risky than XTL Biopharmaceutica. The stock trades about -0.23 of its potential returns per unit of risk. The XTL Biopharmaceuticals Ltd is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  256.00  in XTL Biopharmaceuticals Ltd on September 27, 2024 and sell it today you would lose (73.00) from holding XTL Biopharmaceuticals Ltd or give up 28.52% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

ProPhase Labs  vs.  XTL Biopharmaceuticals Ltd

ProPhase Labs

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ProPhase Labs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

XTL Biopharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days XTL Biopharmaceuticals Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with ProPhase Labs and XTL Biopharmaceutica

The main advantage of trading using opposite ProPhase Labs and XTL Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ProPhase Labs position performs unexpectedly, XTL Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XTL Biopharmaceutica will offset losses from the drop in XTL Biopharmaceutica's long position.

The idea behind ProPhase Labs and XTL Biopharmaceuticals Ltd pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.